Sara Coca Membribes, GU Clinical Research Fellow at Barts Health NHS Trust, shared on X:
“Presidential Session and concomitant publication in Annals of Oncology.
ARTEMIS-011 Ris-Rez vs gem/doce in prev treated osteosarcoma shows PFS benefit but modest ORR and OS immature.
A landmark phase III result opening the door to ADCs in osteosarcoma.”
You can also read: ARTEMIS-011 at ESMO 2026: Risvutatug Rezetecan Significantly Improves PFS in Relapsed or Refractory Osteosarcoma
